PRESS RELEASE Wolters Kluwer publishes agenda for 2026 Annual General Meeting Alphen aan den Rijn — April 9, 2026 — Wolters Kluwer, a global leader in professional information solutions, software, and services, today published the agenda and all related materials for the 2026 Annual General Meeting of Shareholders (AGM) to be held on May 21, 2026. The 2025 Financial statements, as included in the Annual Report, will be proposed for adoption at the AGM. The agenda further includes a proposal to distribute a total dividend over the 2025 financial year of €2.52 per ordinary share. If approved, this will result in a final dividend of €1.59 per ordinary share. The agenda includes proposals to reappoint Ms. Heleen Kersten as member of the Supervisory Board and to appoint Mr. Maarten de Vries as member of the Supervisory Board. The agenda also...

TomTom launches Unified Speed Restrictions for higher-precision speed data across ISA, ADAS and automationTomTom launches Unified Speed Restrictions for higher-precision speed data across ISA, ADAS and automationAMSTERDAM, April 09, 2026 (GLOBE NEWSWIRE) — TomTom (TOM2), the specialist in mapping and location technology, today announced the launch of Unified Speed Restrictions, a new service designed to deliver fresher, more accurate speed information. Built to support global regulatory frameworks and the next generation of Advanced Driver Assistance Systems (ADAS), Unified Speed Restrictions helps carmakers achieve speed accuracy beyond Intelligent Speed Assistance (ISA) requirements. ISA plays a crucial role in road safety and driver comfort by helping vehicles stay aligned with the correct speed limit. However, real...

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference: Van Lanschot Kempen Life Sciences ConferenceDate: April 16, 2026Location: Amsterdam, The NetherlandsAttendee: Julia Neugebauer, PhD, COO ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking...

Technip Energies awarded contract for Long Son Petrochemicals enhancement project in Vietnam@TechnipEnergiesTechnip Energies (PARIS:TE) has been awarded a contract by Long Son Petrochemicals Co., Ltd. (LSP) for its Long Son Petrochemicals Enhancement (LSPE) project, located on Long Son Island, Vietnam. The contract covers engineering and procurement services, site assistance, and the supply of proprietary burners for the plant’s cracking furnaces. The project will convert the existing steam cracker from naphtha to ethane feedstock using Technip Energies’ proprietary ethylene technologies, including its Ultra Selective Conversion (USC®) furnace design and Heat-Integrated Rectifier System (HRS®), delivering high selectivity, enhanced energy efficiency and optimized ethylene recovery. This strategic initiative will incorporate large...

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S.Builds on pilot programs that demonstrated significant increase in control rates for high blood pressure in pilot settingsEast Hanover, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:Inclusive...

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S.Builds on pilot programs that demonstrated significant increase in control rates for high blood pressure in pilot settingsBasel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:Inclusive...